Incyte Corp. Files 10-Q for Period Ending March 31, 2024
Ticker: INCY · Form: 10-Q · Filed: Apr 30, 2024 · CIK: 879169
Sentiment: neutral
Topics: 10-Q, Financials, Product Revenue, Incyte Corp, Quarterly Report
TL;DR
<b>Incyte Corp. filed its Q1 2024 10-Q, detailing product revenues and financial position.</b>
AI Summary
INCYTE CORP (INCY) filed a Quarterly Report (10-Q) with the SEC on April 30, 2024. Incyte Corp. reported financial results for the quarter ended March 31, 2024. The filing details financial data including common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings for various periods. Specific product revenues for JAKAFI, Opzelura, ICLUSIG, Pemazyre, MINJUVIMONJUVI, and ZYNYZ are provided for Q1 2024 and Q1 2023. Royalty revenues from Jakavi are also detailed for Q1 2024 and Q1 2023. Milestone and contract revenues are reported for Q1 2024 and Q1 2023.
Why It Matters
For investors and stakeholders tracking INCYTE CORP, this filing contains several important signals. This filing provides a quarterly update on Incyte's financial performance, crucial for investors tracking revenue streams from key products like JAKAFI and Opzelura. The detailed breakdown of revenue segments and balance sheet components offers insights into the company's financial health and operational progress.
Risk Assessment
Risk Level: medium — INCYTE CORP shows moderate risk based on this filing. The company's financial performance is subject to the inherent risks of the pharmaceutical industry, including regulatory approvals, market competition, and patent expirations, as indicated by the detailed revenue segments and the need for ongoing product development.
Analyst Insight
Monitor the revenue growth of key products like Opzelura and JAKAFI in subsequent filings to assess Incyte's market position and future profitability.
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| JAKAFI | ||
| Opzelura | ||
| ICLUSIG | ||
| Pemazyre |
Key Numbers
- 2024-03-31 — Period End Date (Conformed period of report)
- 2024-04-30 — Filing Date (Filed as of date)
- Q1 2024 — Reporting Quarter (Fiscal year end and quarter)
- Q1 2023 — Prior Year Quarter (Comparison period)
Key Players & Entities
- INCYTE CORP (company) — Filer name
- 2024-03-31 (date) — Conformed period of report
- 2024-04-30 (date) — Filed as of date
- 1801 AUGUSTINE CUT-OFF (address) — Business address street 1
- WILMINGTON (location) — Business address city
- DE (location) — Business address state
- 19803 (postal_code) — Business address zip
- 3024986700 (phone_number) — Business phone
FAQ
When did INCYTE CORP file this 10-Q?
INCYTE CORP filed this Quarterly Report (10-Q) with the SEC on April 30, 2024.
What is a 10-Q filing?
A 10-Q is a quarterly financial report with unaudited financials, management discussion, and interim business updates. This particular 10-Q was filed by INCYTE CORP (INCY).
Where can I read the original 10-Q filing from INCYTE CORP?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by INCYTE CORP.
What are the key takeaways from INCYTE CORP's 10-Q?
INCYTE CORP filed this 10-Q on April 30, 2024. Key takeaways: Incyte Corp. reported financial results for the quarter ended March 31, 2024.. The filing details financial data including common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings for various periods.. Specific product revenues for JAKAFI, Opzelura, ICLUSIG, Pemazyre, MINJUVIMONJUVI, and ZYNYZ are provided for Q1 2024 and Q1 2023..
Is INCYTE CORP a risky investment based on this filing?
Based on this 10-Q, INCYTE CORP presents a moderate-risk profile. The company's financial performance is subject to the inherent risks of the pharmaceutical industry, including regulatory approvals, market competition, and patent expirations, as indicated by the detailed revenue segments and the need for ongoing product development.
What should investors do after reading INCYTE CORP's 10-Q?
Monitor the revenue growth of key products like Opzelura and JAKAFI in subsequent filings to assess Incyte's market position and future profitability. The overall sentiment from this filing is neutral.
Risk Factors
- Revenue Recognition [medium — financial]: The company's revenue is derived from product sales, royalties, and milestone and contract revenues, each subject to specific recognition criteria and potential fluctuations.
- Product Demand and Competition [medium — market]: Demand for Incyte's products is influenced by market acceptance, physician prescribing patterns, and competition from other pharmaceutical companies.
- Regulatory Approvals and Compliance [high — regulatory]: The company's ability to generate revenue is dependent on obtaining and maintaining regulatory approvals for its products and complying with stringent healthcare regulations.
Filing Stats: 4,492 words · 18 min read · ~15 pages · Grade level 17.9 · Accepted 2024-04-30 16:02:03
Filing Documents
- incy-20240331.htm (10-Q) — 1278KB
- incy-3312024xex311.htm (EX-31.1) — 10KB
- incy-3312024xex312.htm (EX-31.2) — 10KB
- incy-3312024xex321.htm (EX-32.1) — 4KB
- incy-3312024xex322.htm (EX-32.2) — 4KB
- 0000879169-24-000077.txt ( ) — 6841KB
- incy-20240331.xsd (EX-101.SCH) — 56KB
- incy-20240331_cal.xml (EX-101.CAL) — 66KB
- incy-20240331_def.xml (EX-101.DEF) — 319KB
- incy-20240331_lab.xml (EX-101.LAB) — 651KB
- incy-20240331_pre.xml (EX-101.PRE) — 515KB
- incy-20240331_htm.xml (XML) — 743KB
: FINANCIAL INFORMATION
PART I: FINANCIAL INFORMATION 3 Item 1.
Financial Statements
Financial Statements 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Income (Loss) 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Condensed Consolidated Financial Statements 8 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 23
Forward-Looking Statements
Forward-Looking Statements 23 Summary Risk Factors 26 Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 51 Item 4.
Controls and Procedures
Controls and Procedures 52
: OTHER INFORMATION
PART II: OTHER INFORMATION Item 1A.
Risk Factors
Risk Factors 52 Item 5. Other Information 80 Item 6. Exhibits 81
Signatures
Signatures 82 2 Table of Contents
: FINANCIAL INFORMATION
PART I: FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements INCYTE CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except number of shares and par value) March 31, 2024 December 31, 2023* (unaudited) ASSETS Current assets: Cash and cash equivalents $ 3,346,204 $ 3,213,376 Marketable securities—available-for-sale (amortized cost $ 506,379 and $ 442,816 as of March 31, 2024 and December 31, 2023, respectively; allowance for credit losses $ 0 as of March 31, 2024 and December 31, 2023) 504,484 442,667 Accounts receivable 745,526 743,557 Inventory 63,642 62,972 Prepaid expenses and other current assets 189,235 182,830 Total current assets 4,849,091 4,645,402 Restricted cash 1,627 1,845 Long term investments 287,663 187,716 Inventory 264,292 206,965 Property and equipment, net 719,999 751,513 Finance lease right-of-use assets, net 25,533 25,535 Other intangible assets, net 117,841 123,545 Goodwill 155,593 155,593 Deferred income tax asset 666,566 631,886 Other assets, net 47,400 52,107 Total assets $ 7,135,605 $ 6,782,107 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 164,238 $ 109,601 Accrued compensation 89,109 153,348 Accrued and other current liabilities 1,102,268 935,569 Finance lease liabilities 3,678 3,439 Acquisition-related contingent consideration 37,160 38,422 Total current liabilities 1,396,453 1,240,379 Acquisition-related contingent consideration 164,840 173,578 Finance lease liabilities 28,934 29,162 Other liabilities 151,107 149,151 Total liabilities 1,741,334 1,592,270 Commitments and contingencies (Note 15) Stockholders' equity: Preferred stock, $ 0.001 par value; 5,000,000 shares authorized; none issued or outstanding — — Common stock, $ 0.001 par value; 400,000,000 shares authorized; 224,533,449 and 224,286,862 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 224 224 Additional paid-in capital 5,070,286 5,016,122 Accumulated other comprehensive (lo